Additionally, resistance to cetuximab and panitumumab in metastatic colorectal cancer (mCRC) has been associated with the increased expression of EGFR ligands, structural alterations in EGFR, and autophagy [78]. Here, EGFR is linked to metastatic colorectal cancer.